Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The user is struggling with hair loss despite using finasteride, minoxidil, and ketoconazole, and addressing vitamin D and ferritin deficiencies. They experienced a temporary improvement but are now shedding hair again and feeling stressed.

Dutasteride is often more effective than finasteride for hair regrowth, though it may cause initial shedding. Many users see positive results after several months, with some combining it with minoxidil for better outcomes.

The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.

Switching from finasteride to dutasteride as a treatment for hair loss, with advice given that titrating up to daily use is optimal and results may be seen after one year. Additionally, the user mentioned adding topical minoxidil 5% which has produced good results.

Switching from finasteride to dutasteride can cause increased hair shedding, which may last several months before potential regrowth. Some users suggest combining both medications or waiting up to a year for improvement, while others report better results with finasteride alone.

Hair loss varies due to genetic sensitivity to DHT and other factors. Treatments discussed include finasteride, minoxidil, RU58841, and microneedling.

Microneedling is effective for hair growth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.

Oral minoxidil is more effective than topical minoxidil for hair regrowth but may cause side effects like heart issues and increased body hair. Combining it with finasteride is common for better results, though side effects vary.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

Applying hair loss treatments like minoxidil and finasteride, with concerns about side effects and application timing. Some users experience side effects, while others manage without issues, and there's interest in future treatments like pyrilutamide.

Finasteride may pose a risk during pregnancy, so using a condom is recommended if a partner is pregnant. It is advised to stop finasteride before trying to conceive due to potential effects on fetal development.

The conversation discusses hair loss treatments, focusing on iron supplements for low ferritin levels and considering finasteride and minoxidil if thinning persists. There is debate over starting with finasteride versus dutasteride, with some users advocating for dutasteride due to its potency, while others caution about potential side effects.

Dutasteride's half-life varies with dosage, and lower doses can be effective with fewer side effects compared to finasteride. Some users report different side effects with dutasteride and finasteride, and extreme dosages of dutasteride are unnecessary and potentially harmful.

A user shared that while finasteride improved their hair, it didn't solve all their insecurities, suggesting that self-acceptance is key. Others in the conversation expressed varying opinions, with some feeling that finasteride significantly boosted their confidence and quality of life, while others acknowledged it as a solution to hair loss but not a cure-all for other personal issues.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.